Dr Agarwal's Eye Hospital
- Market cap
- ₹ 2,460 Cr.
- P/E
- 32.4x
- P/B
- 6.92x
- 52-week range
- 4,600 – 6,059.7
- ROE
- 25%
- ROCE
- 17%
- Dividend yield
- 0.1%
- Debt / equity
- 0.94
- Sector
- Healthcare Services
- Industry
- Hospital
- Listed on
- NSE, BSE
About
Dr. Agarwal's Eye Hospital Limited is an India-based company engaged in running, owning and managing eye care hospitals, optical, pharmacies, and related services. The Company provides eye anatomy & treatments, including retina, uvea, cornea, orbit, photocoagulation, vitrectomy, anti VEGF, dry eyes, scleral buckle, pre descemets endothelial keratoplasty (PDEK), refractive surgery and pediatric ophthalmology. It also provides treatment for cataract, glaucoma, squint, diabetic retinopathy, retinal detachment, retinopathy prematurity, macular edema, traumatic cataract, macular hole, posterior subcapsular cataract, rosette cataract and congenital glaucoma. The Company provides its services in various locations in India, including Tamil Nadu, Karnataka, Maharashtra, Kerala, West Bengal, Odisha, Andhra Pradesh, Pondicherry, Gujarat, Rajasthan, Madhya Pradesh, and Andaman.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Hospital: 41 companies →Dr Agarwal's Eye Hospital against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)32.4 against a typical 48.9: cheaper than most peers (1st = cheapest).10th of 40
- Sales growth+22.2% against a typical +21.1% from a year earlier.16th of 34
- Profit growth+35.3% against a typical +13% from a year earlier.9th of 31
- Share price, 3 months+6.9% against a typical −8.8%.9th of 35
- Size₹ 2,459.7 Cr. market value against a typical ₹ 1,306.7 Cr. (1st = largest).16th of 36
Credit ratings
Every rating action on file, newest first, including reaffirmations. Open a row for the agency's reasoning. All credit rating updates
High safety
Rated AA- by ICRA- No warnings from the agency.
| Agency | Current rating | Outlook | As of |
|---|---|---|---|
| CRISIL | Withdrawn | — | 15 Jun 2026 |
| ICRA | [ICRA]AA- | Stable | 23 Feb 2026 |
| Rating | Details | |||||
|---|---|---|---|---|---|---|
| 15 Jun 2026 | Withdrawn | — | — | CRISIL | ₹ 130 Cr. | |
| 23 Feb 2026 | New rating | [ICRA]AA- | — | ICRA | ₹ 140 Cr. |
Financials
Standalone figures in ₹ crore.
| ₹ Cr. | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 84 | 76 | 81 | 100 | 102 | 95 | 100 | 117 | 118 | 116 | 120 | 143 |
| Expenses | 61 | 55 | 56 | 69 | 72 | 69 | 68 | 80 | 78 | 82 | 86 | 100 |
| Operating Profit | 23 | 21 | 24 | 31 | 30 | 26 | 32 | 37 | 40 | 34 | 34 | 43 |
| OPM % | 28% | 27% | 30% | 31% | 29% | 27% | 32% | 32% | 34% | 30% | 28% | 30% |
| Other Income | 1 | 1 | 2 | 0 | 2 | 2 | 0 | 1 | 1 | 3 | 2 | 2 |
| Interest | 2 | 2 | 2 | 3 | 4 | 4 | 3 | 4 | 4 | 2 | 2 | 3 |
| Depreciation | 6 | 7 | 8 | 10 | 9 | 10 | 10 | 11 | 11 | 12 | 12 | 11 |
| Profit before tax | 17 | 13 | 17 | 19 | 19 | 14 | 19 | 23 | 26 | 23 | 21 | 31 |
| Tax % | 24% | 26% | 26% | 25% | 26% | 26% | 14% | 26% | 25% | 26% | 24% | 24% |
| Net Profit | 13 | 9 | 13 | 14 | 14 | 10 | 16 | 17 | 19 | 17 | 16 | 23 |
| EPS in Rs | 26.79 | 20.09 | 27.21 | 30.02 | 30.11 | 22.13 | 34.02 | 36.72 | 39.98 | 35.76 | 33.6 | 48.38 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- 13%
- 5 Years
- 27%
- 3 Years
- 21%
- TTM
- 20%
- 10 Years
- 35%
- 5 Years
- 120%
- 3 Years
- 24%
- TTM
- 32%
- 10 Years
- 38%
- 5 Years
- 68%
- 3 Years
- 35%
- TTM
- —
- 10 Years
- 28%
- 5 Years
- 31%
- 3 Years
- 29%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| Dr Agarwal's Eye Hospital | ₹ 5,339.00 | ₹ 2,460 Cr. | 32.4x | 6.9x | 25% | — |
| Apollo Hospitals Enterprise | ₹ 7,730.00 | ₹ 1,09,249 Cr. | 64.9x | 13.4x | 22% | 7.8% |
| Max Healthcare Institute | ₹ 815.00 | ₹ 79,325 Cr. | 71.3x | 9.9x | 14.3% | 17.2% |
| Fortis Healthcare | ₹ 712.90 | ₹ 53,821 Cr. | 67.2x | 7.2x | 11.1% | 11.7% |
| Aster DM Healthcare | ₹ 644.75 | ₹ 56,272 Cr. | 101.6x | 9.2x | 9.7% | 9.2% |
| Narayana Hrudayalaya | ₹ 1,646.90 | ₹ 33,586 Cr. | 47.5x | 9x | 19.9% | 10.3% |
Management
- Amar Agarwal
- Executive and Non-Independent Chairman of the Board, Managing Director
- Yashwanth Venkat
- Interim Chief Financial Officer
- Meenakshi Jayaraman
- Compliance Officer, Company Secretary
- Saradha Govindarajan
- Compliance Officer
- Athiya Agarwal
- Non-Independent Whole Time Director
- S. Lakshmi Narasimhan
- Company Secretary
Prices are delayed and for information only. Nothing on this page is investment advice.